SIETES :: 92559 citas

Resultados de la búsqueda por OSTEOPOROSIS REFINAR BÚSQUEDA

1.

Anónimo. FDA approves elagolix for endometriosis pain. DIA Daily 2018:25 de julio. [Ref.ID 102722]

2.

Tsourdi E, Rachner TD, Hofbauer LC. Romosozumab versus alendronate and fracture risk in women with osteoporosis. N Engl J Med 2018;378:11 de enero. [Ref.ID 102629]

3.

Lewis JR, Schousboe JT, Prince RL. Romosozumab versus alendronate and fracture risk in women with osteoporosis. N Engl J Med 2018;378:11 de enero. [Ref.ID 102628]

4.

Song GG, Lee YH. Romosozumab versus alendronate and fracture risk in women with osteoporosis. N Engl J Med 2018;378:11 de enero. [Ref.ID 102627]

5.

Anónimo. Teriparatide: Shock and loss of consciousness. Japan . WHO Drug Information 2018;32:18. [Ref.ID 102621]

6.

Davies E. No more vetebroplasty for acute vertebral compression fractures?. BMJ 2018;361:9 de mayo. [Ref.ID 102617]

7.

Firanescu CE, De Vries J, Lodder P, Venmans A, Schoemaker MC, Smeet AJ, Donga E, Juttmann JR, Klazen CAH, Elgersma OEH, Jansen FH, Tielbeek AV, Boukrab I, Schonenberg K, van Rooij WJJ, Hirsch JA, Lohle PNM. Vertebroplasty versus sham procedure for painful acute osteoporotic vertebral compression fractures (VERTOS IV): randomised sham controlled clinical trial. BMJ 2018;361:9 de mayo. [Ref.ID 102616]

8.

Garattini S, Bertele V. Benefits, benefits, once more benefits... with no risk? Stop overlooking the harms of medicines. Eur J Clin Pharmacol 2018;74:marzo. [Ref.ID 102550]

9.

González AV, Coulombe J, Ernst P, Suissa S. Long-term use of inhaled corticosteroids in COPD and the risk of fracture. Chest 2018;153:321-8. [Ref.ID 102538]

10.

Lane S, Lynn E, Shakir S. Investigation assessing the publicly available evidence supporting postmarketing withdrawals, revocations and suspensions of marketing authorisations in the EU since 2012. BMJ Open 2018;8:e019759. [Ref.ID 102510]

11.

Zhao J-G, Zeng X-T, Wang J, Liu L. Association between calcium or vitamin D supplementation and fracture incidence in community-dwelling older adults. A systematic review and meta-analysis. JAMA 2017;318:2466-82. [Ref.ID 102195]

12.

McNeil M. Menopausal hormone therapy. Understanding long-term risks and benefits. JAMA 2017;318:911-3. [Ref.ID 102069]

13.

Sugiyama T. Osteoporotic fractures associated with dabigatran vs warfarin. JAMA 2017;318:90-1. [Ref.ID 102054]

14.

Saag KG, Petersen J, Brandi ML, Karaplis AC, Lorenzton M, Thomas T, Maddox J, Fan M, Meisner PD, Grauer A. Romosozumab or alendronate for fracture prevention in women with osteoporosis. N Engl J Med 2017:11 de septiembre. [Ref.ID 102052]

15.

Anónimo. Diphosphonates: valvulopathies?. Prescrire 2017;37:511-2. [Ref.ID 102010]

16.

de Boissieu P, Kanagaratnam L, Mahmoudi R, Morel A, Dramé M, Trenque T. Adjudication of osteonecrosis of the jaw in phase III randomized controlled trials of denosumab: a systematic review. Eur J Clin Pharmacol 2017;73:517-23. [Ref.ID 101992]

17.

Anónimo. Strontium ranelate discontinued. Prescribing Advice for GPs 2017:1. [Ref.ID 101637]

18.

Davis S, Martyn-St James M, Sanderson J, Stevens J, Goka E, Rawdin A, Sadler S, Wong R, Campbell F, Stevenson M, Strong M, Selby P, Gittoes N. A systematic review and economic evaluation of bisphosphonates for the prevention of fragility fractures. Health Technol Assess 2016;20:1-406. [Ref.ID 101044]

19.

Cosman F, Crittenden DB, Adachi JD, Binkley N, Czerwinski E, Ferrari S, Hofbauer LC, Lau E, Lewiecki EM, Miyauchi A, Zerbini CAF, Milmont CE, Chen L, Maddox J, Meisner PD, Libanati C, Grauer A. Romosozumab treatment in postmenopausal women with osteoporosis. N Engl J Med 2016;375:1532-43. [Ref.ID 100908]

20.

Miller PD, Hattersley G, Riis BJ, Williams GC, Lau E, Russo A, Alexandersen P, Zerbini CAF, Hu M-y, Harris AG, Fitzpatrick LA, Cosman F, Christiansen C, for the ACTIVE Study Investigators. Effect of abaloparatide vs placebo on new vertebral fractures in postmenopausal women with osteoporosis: a randomized clinical trial. JAMA 2016;316:722-33. [Ref.ID 100710]